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OBJECTIVE — To determine whether evidence-based socioculturally adapted collaborative
depression care improves receipt of depression care and depression and diabetes outcomes in
low-income Hispanic subjects.
RESEARCH DESIGN AND METHODS — This was a randomized controlled trial of
387 diabetic patients (96.5% Hispanic) with clinically signiﬁcant depression recruited from two
public safety-net clinics from August 2005 to July 2007 and followed over 18 months. Inter-
vention (INT group) included problem-solving therapy and/or antidepressant medication based
on a stepped-care algorithm; ﬁrst-line treatment choice; telephone treatment response, adher-
ence, and relapse prevention follow-up over 12 months; plus systems navigation assistance.
Enhanced usual care (EUC group) included standard clinic care plus patient receipt of depres-
sion educational pamphlets and a community resource list.
RESULTS — INTpatientshadsigniﬁcantlygreaterdepressionimprovement(50%reductionin
SymptomChecklist-20depressionscorefrombaseline;57,62,and62%vs.theEUCgroup’s36,42,
and 44% at 6, 12, and 18 months, respectively; odds ratio 2.46–2.57; P  0.001). Mixed-effects
linear regression models showed a signiﬁcant study group–by–time interaction over 18 months in
diabetessymptoms;anxiety;MedicalOutcomesStudyShort-FormHealthSurvey(SF-12)emotional,
physical, and pain-related functioning; Sheehan disability; ﬁnancial situation; and number of social
stressors (P  0.04 for disability and SF-12 physical functioning, P  0.001 for all others) but no
study group–by–time interaction in A1C, diabetes complications, self-care management, or BMI.
CONCLUSIONS — Socioculturallyadaptedcollaborativedepressioncareimproveddepres-
sion, functional outcomes, and receipt of depression treatment in predominantly Hispanic
patients in safety-net clinics.
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D
iabetes is associated with a twofold
higher risk of comorbid depression
compared with the general popula-
tion, with rates among Hispanics as high
as 33% (1). Greater risk of cardiovascular
illness, functional disability, mortality,
and health service use is found among
Hispanics with comorbid depression and
diabetes, which is particularly important
because Hispanics have a higher preva-
lence of diabetes compared with non-
Hispanic whites (2). Moreover, among
diabetic patients, depression is often per-
sistentandsevere(2),andamongHispan-
ics, difﬁculty with diabetes management
can contribute to depression (3). How-
ever, Hispanics are less likely to be diag-
nosed or to receive depression care and
have lower utilization rates and greater risk
ofdiscontinuingantidepressantsduringthe
ﬁrst 30 days of treatment because of side
effects, socioeconomic barriers, and cul-
tural preferences for psychotherapy (4).
Glycemic control is worse and compli-
cations are high among Hispanics with dia-
betes (5), in part, explained by inadequate
medical and self-care and cultural and eco-
nomic factors (6). Comorbid depression
and diabetes may signiﬁcantly worsen the
course of both disorders, leading to higher
complicationandmortalityrates(7)andto-
talhealthcareexpenditures(8).Depression
may worsen diabetes outcomes via neuro-
biological mechanisms (9) and poor adher-
encetoself-careregimens(10).Insome,but
not all, trials, glucose control has been
shown to improve with depression treat-
ment; however, the prevalence of undiag-
nosed or untreated depression among all
diabetic subjects is high (11).
This randomized clinical trial imple-
mentedahealthserviceseffectivenesstrial
design to test a collaborative care model
aimed at increasing exposure of low-
income,predominantlyHispanicdiabetic
patients (15 non-Hispanics) with co-
morbid depression to evidenced-based
depression psychotherapy and/or phar-
macotherapy to examine both depression
carereceiptandoutcomescomparedwith
usual care. We hypothesized that the in-
tervention (INT group) versus enhanced
usual care (EUC group) would be associ-
ated with improved depressive symptom
outcomes,functioning,qualityoflife,and
A1C levels at 6, 12, and 18 months. So-
ciocultural adaptations (12,13) were
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treatmentengagementandadherence;re-
ducing individual, provider, and system
barriers to care; integrating depression
and diabetes care; and providing cultur-
ally and linguistically competent care.
RESEARCH DESIGN AND
METHODS— The study, approved
by the University of Southern California
Institutional Review Board, was con-
ducted in public community clinics, one
of which provides usual primary care,
whereas the other offers diabetic patients
referred by clinic primary care physicians
(PCPs)aprograminwhichdiabetesnurse
educators provide care coordination,
monitoring, and self-management educa-
tion. Trained bilingual study recruiters
identiﬁed diabetic patients from medical
charts. Patients provided verbal consent
to depression symptom screening; eligi-
ble patients provided written informed
trial consent. Randomization was con-
ducted via a computer-generated random
number in blocks of 10, with random as-
signment number enclosed in sealed en-
velopes; patients selected one of ﬁve
sequential envelopes following baseline
interview. Clinic PCPs and nursing staff
attended a depression treatment didactic
session by the study psychiatrist at study
onset and a refresher midway.
Intervention model
KeyelementsintheMultifacetedDiabetes
and Depression Program are based on ev-
idence-based practice guidelines for pri-
mary care and are responsive to known
barriers to treatment among patients in
public safety-net clinics. The structured
stepped-care algorithm 12-month inter-
vention included 1) problem-solving
therapy(PST)providedbybilingualgrad-
uate social work diabetes depression
clinical specialists (DDCSs) and/or anti-
depressant medications prescribed by
the treating PCP; 2) DDCS monthly tele-
phone follow-up symptom monitoring,
treatment maintenance, and relapse pre-
vention; and 3) care and service system
navigation by the DDCS and an assistant
patientnavigator.Apsychiatristandprin-
cipal investigator (K.E.) provided weekly
telephone DDCS supervision, and, if re-
quested, the psychiatrist provided PCP
antidepressant medication telephone
consultation.
Thealgorithmwasmodeledafterpre-
viousstudies(12,13)andaimedtoensure
that patients received depression treat-
ment consistent with their preference,
clinical presentations, and responses over
time. The algorithm included the follow-
ing: step 1 (weeks 1–8): based on patient
preference, patients start PST or antide-
pressant medication (usually a selective
serotonin reuptake inhibitor titrated
gradually to therapeutic dose); step 2
(weeks 9–12): patients with partial/
nonresponse receive a different antide-
pressant medication or the addition of
antidepressant medication or PST; step 3:
patients with full response move to
monthly maintenance/relapse prevention
telephone monitoring. Nonresponsive
patients were considered for additional
PST, augmentation of low-dose Traz-
odone for insomnia, and referral to spe-
cialty mental health care.
Sociocultural enhancements (13) in-
cluded psychoeducation to dispel treat-
mentmisconceptions,reducestigma,and
enhance therapeutic alliance; patient
choice of ﬁrst-line medication or PST and
family participation; 8–12 PST sessions
(plus booster sessions if indicated and a
PST open-ended patient support group
availableupto12monthsposttreatment);
PST sessions tailored for literacy and idi-
omatic content and linking PST problem-
solving skills training to enhance diabetes
and depression self-management and
coping with socioeconomic stress; and
patient navigation assistance to facilitate
patient-provider communication and ﬁ-
nancial and social resource access.
Enhanced usual care
EUC patients received standard clinic
care and in addition were given patient-
and family-focused depression educa-
tional pamphlets (Spanish or English)
and a community, ﬁnancial, social ser-
vices, transportation, and child care re-
source list. EUC group PCPs were
informed of patient depression diagnoses
and study participation and could pre-
scribeantidepressantmedicationsorrefer
patients to community mental health
care. Patients could seek mental health
treatment.
Data collection
The 20-item Symptom Checklist Depres-
sion Scale (SCL-20) (14) was used as a
reliable and valid measure of depression
in medical populations that has been
shown to be sensitive to change in pri-
mary care studies (Cronbach 0.91).
The Patient Health Questionnaire-9
(PHQ-9) was used because it provides a
dichotomous diagnosis of major depres-
sion, provides a continuous severity
score, and has been found to have 73%
sensitivity and 98% speciﬁcity to a diag-
nosis of probable major depressive disor-
der based on structured psychiatric
interview (15,16). Thus, patients with a
score of 10 are considered to have clin-
ically signiﬁcant depressive symptoms.
Two standard questions from the Struc-
tured Clinical Interview for DSM-IV were
used to assess dysthymia. The Sheehan
Disability Scale was used to rate func-
tional impairment on a 10-point Likert
scale (17). Health-related quality of life
wasassessedusingtheMedicalOutcomes
Study Short-Form Health Survey (SF-12)
Physical and Mental Component Sum-
mary norm-based scores standardized to
the general U.S. population with a mean
( SD) of 50  10. The SF-12 includes
one measure of pain impact that asks re-
spondents to rate pain interference with
normal work on a scale (none 1, extreme
5). The Brief Symptom Inventory (18) as-
sessed anxiety. The Summary of Diabetes
Self-Care Activities Questionnaire as-
sessed self-reported adherence (19). Dia-
betes symptoms were assessed using the
Whitty 9-item questionnaire, which has
been demonstrated to change over time
with effective diabetes treatment (20).
A1C was obtained from medical records
with baseline A1C (last test done before
enrollment) and follow-up A1C (last test
done within 3 months of each postenroll-
ment outcome); antidepressant medica-
tion prescriptions were monitored via
medical records and self-report. Also as-
sessed were self-reported weight and
height (BMI), diabetes complications, co-
morbid medical illness, and socioeco-
nomic stress (ﬁnancial situation, work,
unemployment, ﬁnancial problems, mar-
ital/family conﬂicts, legal and care-giving
problems, and community violence
worry).
Statistical methods
Intent-to-treat analysis was conducted to
evaluate intervention effects. Clinically
meaningful improvement of depressive
symptomswasassessedasa50%reduc-
tion in baseline SCL-20 or PHQ-9; de-
pression remission was assessed by
SCL-20 0.5 or PHQ-9 5. Logistic re-
gression models were conducted to com-
pare the odds of achieving clinically
meaningful improvement (50%
decrease in depressive symptoms), re-
mission of depressive symptoms, or
persistent major depression between en-
hanced usual care and the intervention at
6-, 12-, and 18-month follow-up. General
Ell and Associates
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in SAS Proc Mixed procedure were ﬁtted
withlongitudinaldatafrombaselineto18
monthstoevaluateinterventioneffectson
functional, socioeconomic, and clinical
outcomes (21). Unstructured covariance
was speciﬁed in the mixed-effects model
to account for within-patient correlations
of repeated observations over time. Fixed
effects of time, study group, and their in-
teractions were examined. Both logistic
regression and linear mixed-effects mod-
els were adjusted for clinic site, baseline
depressionseverity(PHQ-9score15vs.
15) and dysthymia, birth place, lan-
guage,andyearsintheU.S.(10vs.10).
Two sensitivity analyses, with the ﬁrst ex-
cluding non-Hispanics and the second ex-
cluding type 1 diabetic patients, were
conducted.AnalysesusedSASsoftwarever-
sion 9.1 (SAS Institute, Cary, NC).
Follow-upstudyattritiondidnotvary
betweengroups(21.6%intheEUCgroup
vs. 21.8% in the INT group at 6 months,
28.4% in the EUC group vs. 26.4% in the
INT group at 12 months, and 29.4% in
the EUC group vs. 25.4% in the INT
group at 18 months) or in patients refus-
ing continuing trial participation or no
longer receiving care at clinics (10.9,
15.5,and17.9%at6,12,and18months,
respectively) (Fig. 1). Baseline depres-
sion, quality-of-life clinical outcomes,
and most demographics were similar be-
tween attrition and retention groups.
Hot-deck imputation as well as multiple
imputations with the predictive model–
based approach were implemented in
SOLAS software version 3.2 (Statistical
Solution, Saugus, MA). Imputed data for
depression improvement and functional
and clinical outcomes were consistent
with results analyzed with all available
data, so we report the latter. With 130
patients per group, 80% power was pro-
jected to detect a minimum 10% absolute
difference in response rates with a two-
tailed  level of 0.05. Enrolling 350 pa-
tients allowed a 30% attrition rate.
Intervention costs were measured as
actualbudget-basedcost(notcharges)for
all DDCS and patient navigator services,
using actual salary plus 32% fringe bene-
ﬁts. Resulting unit costs were $71 per pa-
tient visit (90 min), $35 per DDCS
telephone follow-up (45 min), and $10
for each patient navigation call (10–15
min). Estimates included record-keeping
time. Additional costs included $10 for
relaxation tape, $136 per patient for
DDCS communication with PCP, and
$21 per patient for clinical supervision.
RESULTS
Sample
Study eligible patients with diabetes were
aged 18 years and endorsed one of two
cardinal depression symptoms more than
half the days to nearly every day and
scored 10 on the PHQ-9, indicating a
high likelihood of clinically signiﬁcant
depression. Exclusion criteria were acute
suicidal ideation, a score of 8o nt h e
Alcohol Use Disorders Identiﬁcation Test
alcohol assessment, recent lithium/
antipsychotic medication use, and inabil-
ity to speak English or Spanish. Of 1,803
diabetic patients, 1,729 (95.8%) were
screened (1,255 [72.6%] female); 30%
met depression criteria (female 32.8% vs.
male 23.4%, P  0.001). Excluding pa-
tients meeting alcoholism criteria, acute
suicidality, or other psychiatric condi-
tion, enrollment was 80.5% female and
71.1% male (P  0.04). Of 387 (78.7%)
enrolled patients (15 were non-
Hispanic), 193 were randomized to the
INT group and 194 to the EUC group
(Fig. 1).
Baseline demographic, clinical, and
functionalcharacteristicsaresummarized
in Tables 1 and 2. Patients were predom-
inantly Latina, foreign born, in the U.S.
10 years, unemployed, and had not
completedhighschool.Nearly98%ofpa-
tients had type 2 diabetes (eight had type
1 diabetes). Mean A1C levels were 9.05%
in the EUC group and 9.01% in the INT
group;80%intheEUCgroupand86%in
the INT group had one or more diabetes
complications. Over 60% had BMIs 30
kg/m
2 and 83% had one or more comor-
bid medical conditions. Over 50% of pa-
tients had moderate to severe depression
(PHQ-915);nearly19%reportedahis-
tory of depression. Patients from the two
study clinics varied signiﬁcantly with re-
spect to birth place, language use, diabetes
treatment, mean A1C levels, self-care man-
agement, comorbid medical illness, socio-
economic stress, and depression score.
Intervention implementation
Over the 12-month intervention, 169
(87.6%)patientscompletedaninitialvisit
with a DDCS and 162 (83.9%) continued
intervention treatment. A total of 104
(53.9%) received both PST and antide-
pressant medications, and 49 (25.4%) re-
ceived only PST and 9 (4.7%) received
only antidepressant medications. PST
participants had a mean ( SD) of 8.7 
5.4 sessions. Of 113 INT patients receiv-
ing antidepressant medication, 103 pa-
tients remained on medication for a mean
of 8.8 months over the 12-month inter-
vention, whereas 10 (8.8%) patients dis-
continued antidepressant medication
after 30 days or less. Estimated per-
patient intervention costs totaled $820.
Receipt of depression care
INT patients predominantly chose PST
ﬁrst-line treatment. INT versus EUC pa-
tients were signiﬁcantly more likely to re-
ceive antidepressant medication and/or
counseling/psychotherapy (PST in the INT
group)at12(allPvalues0.001)and18(P
values 0.01 to 0.001) months (Table 2).
Over 12 months, 83.9% of INT patients
received depression treatment (49 PST,
9 antidepressant medication, 104 both)
versus 32.5% of EUC patients (37 antide-
pressantmedication,11self-reportedcoun-
seling, 15 both). Of patients prescribed
antidepressant medication, over 12
months, a dosage increment or change in
type of medication was provided to 63
(55.8%) INT versus 10 (19.2%) EUC pa-
tients.Thirty-ﬁveINTpatientsattendedone
or more PST support group sessions. Pa-
tient satisfaction with emotional care as-
sessed at the 18-month blinded survey
found that INT patients reported signiﬁ-
cantly greater satisfaction (satisﬁed to very
satisﬁed) compared with EUC patients
(89.5 vs. 77.9%; odds ratio 2.43 [95% CI
1.23–4.77]; P  0.01).
Depression outcomes
At 6, 12, and 18 months, INT patients
were signiﬁcantly more likely to have a
50% reduction in SCL-20 baseline
score (57, 62, and 62%) versus EUC pa-
tients (36, 42, and 44%) (adjusted odds
ratio range 2.46–2.57; P  0.001) (Table
2). Signiﬁcant group difference in a
50% decrease in PHQ-9 score also was
found at each follow-up. Intervention pa-
tientshadsigniﬁcantlygreateroddsofde-
pression remission based on SCL-20
0.5 at 6 and 18 months, with similar
trends at 12 months as well as remission
at 6 and 12 months based on PHQ-9 5.
SigniﬁcantlyfewerINTthanEUCpatients
had persistent major depression (i.e.,
PHQ-9 10) at each follow-up. There
were no signiﬁcant interaction effects on
depressionimprovementorremissionbe-
tween study groups and baseline depres-
sion severity, sex, language, time in the
U.S., education, use of insulin, time with
diabetes, glycemic control, or obesity
(BMI 30 kg/m
2) at each follow-up. Sig-
niﬁcant interactions were observed be-
tween study site and study group only for
Collaborative care, depression, and diabetes
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0.03 for interaction; adjusted odds ratio
4.12 [95% CI 1.81–9.42] for El Monte
and 1.28 [0.66–2.49] for Roybal clinic)
andbetweenageandstudygrouponlyfor
depression improvement at 18 months
(P  0.01 for interaction; 0.87 [0.33–
2.27] for patients aged 50 years and
3.80 [2.05–7.02] for patients aged 50
years). Analyses were repeated with the
Hispanic-only and type 2 diabetic patient
samples and the results were identical.
Clinical, functional, and
socioeconomic outcomes
There were signiﬁcant study group–by–
timeinteractionsover18monthsinmean
diabetes symptoms, SF-12 emotional and
physical functioning and pain, Sheehan
Figure 1—Study consort chart.
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of social stressors (Table 2). Comparisons
of adjusted mean scores between study
groups at 6 months found that INT pa-
tients had signiﬁcantly better emotional
functioning and less functional impair-
ment, pain impact, diabetes symptoms,
and likelihood of worsening ﬁnancial situa-
tion; signiﬁcant improvement in ﬁnancial
situation continued at 12 months; and sig-
niﬁcantly improved Mental Component
Summary-12 was still present at 12 and 18
months. No group differences were found
in A1C, diabetes complications, mean self-
care management scores, or BMI over time
or at each follow-up. Again, there were no
signiﬁcant differences in results for Hispan-
ic- or type 2 diabetes–only samples.
Comment
To our knowledge, this is the ﬁrst ran-
domized controlled trial of collaborative
care for predominantly Hispanic patients
with diabetes in public safety-net clinics.
Findings suggest that a collaborative care
model, socioculturally adapted for low-
incomepatients,resultedinsigniﬁcantre-
ductions in depressive symptoms,
improvements in emotional and physical
functional outcomes, and lower burden
ofdiabetessymptomsandpaincompared
with enhanced usual care. The impor-
tance of study ﬁndings is underscored in
view of data that Hispanics in the U.S.
have the highest estimated lifetime risk
for diabetes (males 45.4% and females
52.5%) (22).
Inlightofknownracial/ethnicdispar-
ities in receipt of depression care, it is
noteworthy that INT patients had signiﬁ-
cantlyhigherratesofparticipationinPST,
the length of time in which patients ad-
hered to antidepressant medications, and
the degree of satisfaction with the quality
of depression care. Providing culturally
sensitive acute and maintenance care that
includes facilitating access to socioeco-
nomic resources and is organizationally
integrated within safety-net care systems
is likely to have a marked effect on de-
creasing disparities in depression care
amonglow-incomeandHispanicpatients
with diabetes.
Despite the improvement associated
with the intervention in quality and out-
comes of depression care as well as im-
provements in functioning and decreased
diabetes and pain symptom burden, no
intervention effect on A1C or self-care
management was found. An association
between poorer glycemic control and de-
pression has been frequently reported;
however, results of treating depression
and improving glycemic control are
mixed. The trials reporting a change in
A1C with improvement of depression
were with less representative populations
and often compared an evidence-based
Table 1—Baseline characteristics
Enhanced usual care Intervention P*
n 194 193
Demographics
Female 164 (84.5) 154 (79.8) 0.22
Hispanic 189 (97.4) 183 (94.8) 0.18
Aged 50 years 134 (69.1) 145 (75.1) 0.18
Foreign born 182 (93.8) 170 (88.1) 0.05
Living in the U.S. 10 years 169 (87.1) 181 (94.3) 0.02
Spanish speaking 175 (90.2) 152 (78.8) 0.002
Less than high school education 166 (85.6) 151 (78.2) 0.06
Unemployed 146 (75.3) 157 (81.3) 0.15
Married 97 (50.0) 94 (48.7) 0.80
Study site
El Monte 80 (41.2) 88 (45.6) 0.39
Roybal 114 (58.8) 105 (54.4)
Health insurance/beneﬁts
Medi-Cal/Medicare 36 (18.6) 34 (17.6) 0.24
County-funded program 113 (58.2) 118 (61.1)
None 41 (21.1) 41 (21.2)
Socioeconomic stress
Financial situation getting worse 59 (30.4) 83 (43.0) 0.01
Number of social stressors 3.15  2.38 4.31  2.70 0.001
Clinical characteristics
Forms of diabetes
Type 1 diabetes 6 (3.1) 2 (1.0) 0.16
Type 2 diabetes 188 (96.9) 191 (99.0)
Diabetes duration (years) 7.97  7.35 8.34  7.20 0.62
Diabetes treatment
Oral medication 139 (71.6) 129 (66.8) 0.27
Insulin 28 (14.4) 26 (13.5)
Insulin plus oral medication 20 (10.3) 33 (17.1)
Diet alone or none 7 (3.6) 5 (2.6)
Diabetes complications
None 38 (19.6) 27 (14.0) 0.36
One 82 (42.3) 78 (40.4)
Two 48 (24.7) 58 (30.1)
Three or more 26 (13.4) 30 (15.5)
Diabetes self-management† 3.37  1.45 3.39  1.45 0.89
Whitty-9 diabetes symptoms 2.15  0.75 2.33  0.76 0.02
A1C 7% 153 (82.3) 156 (83.0) 0.85
BMI 30 kg/m
2 114 (59.4) 118 (61.8) 0.63
Comorbid medical illness‡ 156 (80.4) 165 (85.5) 0.18
Sheehan Disability Scale of
functional impairment 5.74  2.84 6.30  2.67 0.05
Chronic pain 51 (26.3) 75 (38.9) 0.01
Taking pain medication 40 (20.6) 63 (32.6) 0.01
Depression SCL-20 1.41  0.70 1.70  0.73 0.001
Dysthymic disorder 95 (49.0) 119 (61.7) 0.01
History of major depression 29 (14.9) 45 (23.3) 0.04
Taking psychotropic medication 25 (12.9) 36 (18.7) 0.12
Depression/anxiety counseling§ 20 (10.3) 29 (15.0) 0.16
Data are means  SD or frequency (%). *t test for continuous data or 
2 test for categorical data. †Diet,
exercise, blood glucose testing, and foot care. ‡Hypertension; arthritis; or eye, gastrointestinal, kidney, or
heart disease. §Received from a doctor, social worker, or psychologist, some of whom were also taking
psychotropic medication.
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education to diabetes education alone
(23). There is evidence that Hispanics re-
port self-monitoring of blood glucose as
being very difﬁcult (24), while in this
study, patients often expressed to the de-
pression care manager that general man-
agement of diabetes was socially and
economically stressful.
Improving depression symptoms in
patients with diabetes in prior collabora-
tive care studies has been shown to be
associated in comparisons with usual pri-
mary care with a high probability of
achieving savings in total ambulatory
medical costs (8). The higher costs asso-
ciated with providing enhanced mental
health care were offset by greater savings
in medical costs (8). Black et al. (25)
found in a large longitudinal study of an
aging Hispanic population in the south-
westernU.S.thatdepressionmarkedlyin-
creases the risk in patients with diabetes
of macro- and microvascular complica-
tions, incident physical disability, and
mortality. Therefore, further studies are
needed to ascertain whether improving
outcomes of depression in patients with
diabetes could decrease disability, com-
plications, mortality, and medical costs.
Study results are encouraging and are
consistent with other recent studies that
have found that depression care manage-
mentimprovementstrategiesareeffective
over time among low-income and ethnic
minority populations (12). Improving
treatment of depression by integrating a
depression specialist (supervised by a
psychiatrist) into primary care along with
long-term follow-up may be especially
helpful in view of the challenges faced by
physicians in community safety-net clin-
ics. Ensuring that linguistic, cultural, and
economic factors are incorporated with
collaborative care management that in-
cludes mental health personnel is also
likely to reduce disparities in acceptance
andreceiptoftreatment.Of17clinicphy-
sicians, clinic medical directors, and
nursingstaffinterviewed,allreportedsat-
isfactionwiththeinterventionmodel,and
the sustainability of the model is under
active consideration. Our culturally fo-
cused recruitment and follow-up out-
reach efforts are likely to have reduced
potential attrition rates that did not vary
betweenstudygroupsandresultedinbet-
ter-than-usual geographic mobility of the
study population in these safety net
clinics.
Table 2—Receipt of depression care and clinical, functional, and socioeconomic outcomes
Enhanced
usual care Intervention P*
Time-by-group
interaction, P*
Antidepressant receipt NA
Baseline 24 (12.7) 36 (18.9) 0.08
Over 12 months 52 (26.8) 113 (58.5) 0.001
18-month follow-up 27 (19.7) 52 (36.1) 0.002
PST or counseling receipt NA
Baseline 20 (10.3) 29 (15.0) 0.11
Over 12 months 26 (13.4) 153 (79.3) 0.001
18-month follow-up 17 (12.4) 35 (24.3) 0.01
Any depression treatments NA
Baseline 30 (15.5) 43 (22.3) 0.07
Over 12 months 63 (32.5) 162 (83.9) 0.001
18-month follow-up 33 (24.1) 66 (45.8) 0.001
Response (50% SCL-20 reduction) NA
6-month follow-up 55 (36.4) 86 (57.0) 0.001
12-month follow-up 59 (42.4) 88 (62.0) 0.001
18-month follow-up 60 (43.8) 89 (61.8) 0.001
Remission (SCL-20 0.5) NA
6-month follow-up 42 (27.8) 58 (38.4) 0.01
12-month follow-up 49 (35.3) 56 (39.4) 0.09
18-month follow-up 48 (35.0) 58 (40.3) 0.04
A1C 0.93
Baseline 9.05  2.22 9.01  2.15 0.98
6-month follow-up 8.42  2.00 8.45  2.06 0.85
12-month follow-up 8.59  2.26 8.52  2.01 0.98
18-month follow-up 8.50  2.17 8.34  2.04 0.57
Whitty-9 diabetes symptoms 0.001
Baseline 2.15  0.75 2.33  0.76 0.07
6-month follow-up 1.79  0.65 1.65  0.59 0.003
12-month follow-up 1.69  0.56 1.66  0.57 0.18
18-month follow-up 1.74  0.64 1.79  0.71 0.85
Sheehan Disability Scale of
functional impairment 0.04
Baseline 5.74  2.84 6.30  2.67 0.47
6-month follow-up 3.55  2.90 3.07  2.93 0.01
12-month follow-up 3.17  3.04 2.93  3.12 0.06
18-month follow-up 3.18  2.89 3.28  3.13 0.40
Pain impact 0.001
Baseline 2.66  1.34 2.91  1.24 0.22
6-month follow-up 2.59  1.33 2.23  1.23 0.001
12-month follow-up 2.55  1.39 2.44  1.32 0.12
18-month follow-up 2.36  1.41 2.54  1.32 0.50
Physical Component Summary-12
scale 0.04
Baseline 36.57  9.31 34.77  8.88 0.26
6-month follow-up 39.32  10.81 40.76  11.28 0.04
12-month follow-up 40.78  11.68 38.81  11.14 0.54
18-month follow-up 41.15  10.89 39.87  11.70 0.76
Mental Component Summary-12
scale 0.001
Baseline 34.06  9.63 32.27  8.48 0.40
6-month follow-up 42.15  12.27 46.21  10.33 0.001
12-month follow-up 43.60  12.46 47.31  11.48 0.001
18-month follow-up 43.49  11.66 45.10  12.19 0.03
Continued on facing page
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Not unique to health services effectiveness
trials,ourstudydesignmayhavebiasedour
comparisons in favor of the EUC group. In-
creasedprescriptionofantidepressantmed-
ications over baseline among usual care
patients may be attributable in part to the
following enhanced usual care design: all
patients were screened and clinic physi-
cians were notiﬁed of patients meeting
study criteria, all physicians participated in
the depression care didactic sessions and
were given a copy of the stepped-care algo-
rithm,andacutelysuicidalpatientswerere-
ferred for further clinical evaluation and
treatment. Because the same practitioners
treatedbothinterventionandEUCpatients,
there may have also been a spillover effect
onqualityofdepressiontreatment.EUCpa-
tients may have also beneﬁted from having
received the linguistically and idiomatically
adapted patient and family educational
pamphletsandtheinformationprovidedon
available supportive services. These biases
maycontributetoanunderestimationofthe
effectiveness of the intervention compared
with usual care outside a research trial. Ad-
ditional limitations include our reliance on
self-reports of chronic medical conditions
andpotentiallyunderreportingofuseofan-
tidepressants and psychotherapy.
CONCLUSIONS — Socioculturally
and organizationally adapted collabora-
tive care is feasible and effective in im-
proving quality of depression treatment
and depressive and functional outcomes
inalow-income,predominantlyHispanic
population in safety-net clinics. To re-
duce disparities in depression care, these
resultssuggestthatdespiteorganizational
obstacles inherent to safety-net clinics,
physicians should be aware of the in-
creased risk of depressive symptoms in
patients with diabetes and consider ways
to routinely screen and implement socio-
culturally adapted collaborative depres-
sion care management.
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